A retrospective study to determine correlation between Ustekinumab drug level and clinical outcomes in crohn's disease subjects (mUST-DECIDE study)
Latest Information Update: 23 Aug 2021
Price :
$35 *
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms mUST-DECIDE study
- 17 Aug 2021 Results published in the Digestive Diseases and Sciences
- 10 Jul 2020 New trial record
- 19 May 2020 Results (n=53) of follow-up analysis published in Gasteroenterology in conjunction with Digestive Disease Week 2020